Description Ocrelizumab (2nd Generation Anti-CD20) is a humanized monoclonal antibody directed against the CD20 surface antigen on human B-cells. Anti-CD20 antibodies work by binding to a particular protein (the CD20 antigen) on the surface of normal and malignant B-cells. From there, they recruit the body's natural defenses to attack and kill the marked B-cells.

Development Status Phase III clinical trials are ongoing evaluating ocrelizumab for rheumatoid arthritis and lupus nephritis; and a Phase II clinical trial for relapsing remitting multiple sclerosis is ongoing.

This molecule is being developed in collaboration with Biogen Idec Inc.

Our collaborator Biogen Idec disagreed over decision-making rights for certain of the next-generation anti-CD20 products under our 2003 collaboration agreement. The disputed issues were submitted to arbitration in San Francisco, California, which issued a ruling in June 2009. Genentech is satisfied with the outcome, which we believe has advantages to both parties.

Read more about the arbitration panel decision.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

July 2009